Jeroen Jansen, PhD
Associate Professor
Clinical Pharmacy
School of Pharmacy

Jeroen has worked on research to understand the clinical and economic value of healthcare interventions. His research has frequently been conducted in the context of health technology assessment (HTA), with a focus on comparative effectiveness and cost-effectiveness. Prompted by the challenges encountered in applied research projects, Jeroen has performed methodological research. Notable contributions are the development of novel statistical methods to overcome the typical challenges in model-based cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. Furthermore, Jeroen led initiatives to develop guidance for consumers and producers of network meta-analysis studies. He has promoted a more transparent and credible approach to model-based health economic evaluations and led the development of open-source simulation models to illustrate its feasibility. Jeroen has been involved in the ongoing development of an R software package to develop simulation models for health economic evaluations.

Jeroen’s current research interests are the clinical and economic value of precision medicine, incorporating health disparities in health economic modeling studies, and statistical methods for evidence synthesis.

• Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2023 Park JE, Campbell H, Towle K, Yuan Y, Jansen JP, Phillippo D, Cope S
• The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2023 Jansen JP, Brewer IP, Chung S, Sullivan P, Espinosa OD, Grossman JP
• Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis.
  medRxiv : the preprint server for health sciences 2023 Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP
• The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2023 Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA
• Multi-state network meta-analysis of progression and survival data.
  Statistics in medicine 2023 Jansen JP, Incerti D, Trikalinos TA
• Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
  Journal of comparative effectiveness research 2023 Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR
• A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2022 Cope S, Chan K, Campbell H, Chen J, Borrill J, May JR, Malcolm W, Branchoux S, Kupas K, Jansen JP
• Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
  Leukemia & lymphoma 2022 Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, Zheng Y, Snider JT, Locke FL
• Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias.
  Medical decision making : an international journal of the Society for Medical Decision Making 2022 Thom H, Leahy J, Jansen JP
• Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials.
  BMC medicine 2021 Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, Mullins CD, Willke RJ, Orsini LS
• Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
  Leukemia & lymphoma 2021 Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S
• Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis
  Clinical Kidney Journal 2021 Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R.
• Complicated legacies: The human genome at 20.
  Science (New York, N.Y.) 2021 Jones KM, Cook-Deegan R, Rotimi CN, Callier SL, Bentley AR, Stevens H, Phillips KA, Jansen JP, Weyant CF, Roberts DE, Zielinski D, Erlich Y, Garrison NA, Carroll SR, Ossorio PN, Moreau Y, Wang M
• Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews.
  Systematic reviews 2020 Popoff E, Besada M, Jansen JP, Cope S, Kanters S
• Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.
  Journal of comparative effectiveness research 2020 Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y
• The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
  Journal of managed care & specialty pharmacy 2020 Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS
• Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020 Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL
• Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.
  BMJ open 2020 Thom H, Jansen J, Shafrin J, Zhao L, Joseph G, Cheng HY, Gupta S, Shah N
• KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
  Cancer treatment and research communications 2020 Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, Rojubally A, Jansen J, Druyts E
• Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020 Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL
• Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis.
  Clinical kidney journal 2020 Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick RJ
• Heterogeneity and subgroup analysis in network meta-analysis
  In: Ting N, Cappelleri J, Ho S, Chen G. (editors). Design and analysis of subgroups with biopharmaceutical applications. Emerging topics in statistics and biostatistics. Springer, Cham 2020 Jansen JP
• Multivariate network meta-analysis of survival function parameters.
  Research synthesis methods 2020 Cope S, Chan K, Jansen JP
• Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020 Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP
• The economic burden of kidney graft failure in the United States.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020 Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL
• Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.
  PharmacoEconomics 2019 Jansen JP, Incerti D, Linthicum MT
• Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
  Advances in therapy 2019 Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM
• Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
  BMC medical research methodology 2019 Cope S, Ayers D, Zhang J, Batt K, Jansen JP
• Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
  Journal of comparative effectiveness research 2019 Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y
• Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
  Journal of neurology 2019 Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A
• Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Garrison LP, Jansen JP, Devlin NJ, Griffin S
• R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Incerti D, Thom H, Baio G, Jansen JP
• Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System.
  Journal of managed care & specialty pharmacy 2019 Jansen JP, Incerti D, Curtis JR
• Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact.
  Statistics in medicine 2019 Leahy J, Thom H, Jansen JP, Gray E, O'Leary A, White A, Walsh C
• Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
  Advances in therapy 2019 Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM
• The number needed to treat and relevant between-trial comparisons of competing interventions.
  ClinicoEconomics and outcomes research : CEOR 2018 Jansen JP, Khalid JM, Smyth MD, Patel H
• Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
  Clinical research in cardiology : official journal of the German Cardiac Society 2018 Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G
• An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
  Health policy (Amsterdam, Netherlands) 2018 Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, Penrod JR, Jansen J
• Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
  PloS one 2018 Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A
• Network Meta‐Analysis for Decision Making
  Network Meta‐Analysis for Decision Making 2018 Dias S, Ades AE. Welton N, Jansen JP, Sutton A.
• An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
  Journal of medical economics 2017 Evans M, Billings LK, Håkan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, Jansen JP
• Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
  Journal of medical economics 2017 Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V
• Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jansen JP
• Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
  Journal of medical economics 2017 Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, Jansen JP
• Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression.
  Clinical and experimental rheumatology 2017 Druyts E, Palmer JB, Balijepalli C, Chan K, Fazeli MS, Herrera V, Jansen JP, Park JJH, Kanters S, Reimold A
• Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
  Diabetes therapy : research, treatment and education of diabetes and related disorders 2016 Lorenzi M, Ploug UJ, Langer J, Skovgaard R, Zoratti M, Jansen J
• Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
  Clinical therapeutics 2016 Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV
• Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.
  BMC musculoskeletal disorders 2016 Jansen JP, Vieira MC, Bradley JD, Cappelleri JC, Zwillich SH, Wallenstein GV
• Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
  Journal of neurology 2016 Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A
• Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis.
  BMC medical informatics and decision making 2015 Broekhuizen H, Groothuis-Oudshoorn CG, Hauber AB, Jansen JP, IJzerman MJ
• Erratum to: A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
  Infectious diseases and therapy 2015 Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E
• Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing.
  Current medical research and opinion 2015 Szabo SM, Hedegaard M, Chan K, Thorlund K, Christensen R, Vorum H, Jansen JP
• A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
  Infectious diseases and therapy 2015 Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E
• The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
  Annals of internal medicine 2015 Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D
• Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
  Journal of managed care & specialty pharmacy 2015 Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP
• Network meta-analysis of longitudinal data using fractional polynomials.
  Statistics in medicine 2015 Jansen JP, Vieira MC, Cope S
• Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
  Journal of medical economics 2015 Toor K, Druyts E, Jansen JP, Thorlund K
• Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015 Cope S, Clemens A, Hammès F, Noack H, Jansen JP
• Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer.
  JAMA 2015 Mills EJ, Jansen JP, Kanters S
• Incorporating alternative design clinical trials in network meta-analyses.
  Clinical epidemiology 2014 Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ
• Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis.
  JAMA 2014 Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, Ball GD, Busse JW, Thorlund K, Guyatt G, Jansen JP, Mills EJ
• Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
  Health and quality of life outcomes 2014 Jansen JP, Buckley F, Dejonckheere F, Ogale S
• A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.
  BMC medicine 2014 Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P
• Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2014 Ellis AG, Reginster JY, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP
• Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
  Current medical research and opinion 2014 Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP
• Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making.
  BMC medical research methodology 2013 Cope S, Jansen JP
• Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
  Respiratory research 2013 Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P
• A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
  Journal of pain and symptom management 2013 Zeppetella G, Davies A, Eijgelshoven I, Jansen JP
• Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers.
  BMC medicine 2013 Jansen JP, Naci H
• Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013 Cope S, Ouwens MJ, Jansen JP, Schmid P
• Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes.
  BMC medical research methodology 2012 Jansen JP, Cope S
• Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
  The oncologist 2012 Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S
• Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
  International journal of chronic obstructive pulmonary disease 2012 Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP
• Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
  BMC pulmonary medicine 2012 Cope S, Zhang J, Williams J, Jansen JP
• A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
  Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2012 Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G
• Economic outcomes of treatment for ureteral and renal stones: a systematic literature review.
  The Journal of urology 2012 Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE
• Accounting for correlation in network meta-analysis with multi-arm trials.
  Research synthesis methods 2012 Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ
• Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials.
  The Journal of urology 2012 Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE
• Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons.
  Journal of clinical epidemiology 2012 Jansen JP, Schmid CH, Salanti G
• Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012 Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP
• Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison.
  The open rheumatology journal 2012 Stam W, Jansen J, Taylor S
• Epidemiology of HIV-related neuropathy: a systematic literature review.
  AIDS research and human retroviruses 2011 Ghosh S, Chandran A, Jansen JP
• Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
  HIV clinical trials 2011 Vieira MC, Kumar RN, Jansen JP
• Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.
  International journal of rheumatology 2011 Jansen JP, Taylor SD
• Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
  International journal of chronic obstructive pulmonary disease 2011 Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP
• Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2011 Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A
• Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2011 Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC
• Network meta-analysis of parametric survival curves.
  Research synthesis methods 2011 Ouwens MJ, Philips Z, Jansen JP
• An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2011 Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP
• Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
  Scandinavian journal of infectious diseases 2011 Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP
• Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.
  Current medical research and opinion 2010 van de Kerkhof P, de Peuter R, Ryttov J, Jansen JP
• The critical role of observational evidence in comparative effectiveness research.
  Health affairs (Project Hope) 2010 Fleurence RL, Naci H, Jansen JP
• The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
  Seminars in arthritis and rheumatism 2010 Jansen JP, Bergman GJ, Huels J, Olson M
• Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
  Annals of hematology 2010 Jansen JP, O'Sullivan AK, Lugtenburg E, Span LF, Janssen JJ, Stam WB
• Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
  Seminars in arthritis and rheumatism 2010 Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP
• Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
  PharmacoEconomics 2010 Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W
• Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer
  Curr Med Res Opin 2010 Vissers DCJ, Nolte T, Stam WB, Lenre M, Jansen J.
• Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
  Head & neck 2009 Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP
• Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
  Current medical research and opinion 2009 Jansen JP, Bergman GJ, Huels J, Olson M
• Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009 Jansen JP, Kumar R, Carmeli Y
• Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
  PharmacoEconomics 2009 Jansen JP, Kumar R, Carmeli Y
• Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
  European journal of haematology 2008 Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP
• Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008 Stam WB, Aversa F, Kumar RN, Jansen JP
• Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008 Jansen JP, Crawford B, Bergman G, Stam W
• Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
  Current medical research and opinion 2008 Jansen JP, Gaugris S, Bergman G, Sen SS
• Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
  Current medical research and opinion 2007 Jansen JP, Pellissier J, Choy EH, Ostor A, Nash JT, Bacon P, Hunsche E
• A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
  European journal of haematology 2007 Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP
• Predicting the long term course of low back pain and its consequences for sickness absence and associated work disability.
  Occupational and environmental medicine 2006 Burdorf A, Jansen JP
• Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons.
  Current medical research and opinion 2006 Jansen JP
• Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2006 Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A
• The relations between psychosocial factors at work and health status among workers in home care organizations.
  International journal of behavioral medicine 2006 Eriksen HR, Ihlebaek C, Jansen JP, Burdorf A
• Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
  Current medical research and opinion 2005 Jansen JP, Meis JF, Blijlevens NM, van't Wout JW
• Dose-response relations between occupational exposures to physical and psychosocial factors and the risk of low back pain.
  Occupational and environmental medicine 2004 Jansen JP, Morgenstern H, Burdorf A
• Effects of measurement strategy and statistical analysis on dose-response relations between physical workload and low back pain.
  Occupational and environmental medicine 2003 Jansen JP, Burdorf A
• Exposure assessment and its effect on the associations of physical load and back disorders
  Arch Public Health 2002 Jansen JP, Burdorf A
• A novel approach for evaluating level, frequency and duration of lumbar posture simultaneously during work.
  Scandinavian journal of work, environment & health 2001 Jansen JP, Burdorf A, Steyerberg E